CMAX Clinical Research Pty Ltd
Adelaide, Australia
NCT Number: NCT04110886
This is a A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of a kappa receptor agonist HSK21542 in Healthy Volunteers.
The study will enroll approximately 50 adults. The anticipated study duration will be up to 6 months.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Adelaide, Australia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single dose, injection, starting dose of 0.2ug escalating up to 20ug
Single dose, injection matching placebo
Time frame: Between screening and 7-9 days after dosing
To evaluate the safety and tolerability of HSK21542 in comparison with placebo after a single injection in healthy subjects in terms of adverse events
Time frame: Between screening and 7-9 days after dosing
To evaluate the safety and tolerability of HSK21542 in comparison with placebo after a single injection in healthy subjects in terms of abnormal physical examination/ abnormal vital signs/ abnormal laboratory parameters
Time frame: From the start of administration to 24 hours after administration
Maximum (peak) plasma drug concentration
Time frame: From the start of administration to 24 hours after administration
Time to reach maximum (peak) plasma concentration following drug administration
Time frame: From the start of administration to 24 hours after administration
Elimination half-life
Time frame: From the start of administration to 24 hours after administration
Area under the plasma concentration-time curve from time zero to time t.
Time frame: From the start of administration to 24 hours after administration
Area under the plasma concentration-time curve from time zero to infinity
Time frame: From the start of administration to 24 hours after administration
Apparent total body clearance of the drug from plasma
Time frame: From the start of administration to 24 hours after administration
Apparent volume of distribution
Sichuan Haisco Pharmaceutical Group Co., Ltd
Industry
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of a Kappa Receptor Agonist HSK21542 in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01752322
Chronic Pain, Nervous System Diseases
Klagenfurt, Austria
View Trial DetailsNCT04068350
Chronic Pain, Neurologic Manifestations
View Trial DetailsNCT04838028
Chronic Pain, Neurologic Manifestations
View Trial DetailsNCT05662566
Central Sensitisation, Chronic Pain
Copenhagen, Denmark
View Trial Details